Company: CI
Filing Date: 2025-03-14
Form Type: DEF 14A
Source: 0001739940-25-000015
Chunk: 65

Company: Cigna Group
Filing Date: 2025-03-14
Form: DEF 14A
Chunk 65
---
 goals. The Committee considered Mr. Cordani’s recommendations when determining EIP awards. While not exhaustive, below are certain key factors the Committee considered when making award determinations.

| The Cigna Group| 2025 Notice of Annual Meeting of Shareholders and Proxy Statement |     | 67 |

| COMPENSATION MATTERS |

Mr. Evanko. As Executive Vice President and Chief Financial Officer, The Cigna Group, and President and Chief Executive Officer, Cigna Healthcare, Mr. Evanko continued to support and enable the achievement of the Company’s financial objectives while also leading the Cigna Healthcare business. Mr. Evanko provided critical guidance and leadership to many of the Company’s strategic initiatives throughout the year, including preparing for the divestiture of the Medicare Advantage businesses to HCSC. During 2024, Mr. Evanko successfully led the strategic management and deployment of the Company’s capital and supported actions leading to significant operating expense savings, while continuing to strengthen investor communications. While 2024 Cigna Healthcare financial results were impacted by higher-than-anticipated medical costs in our stop loss product within Cigna Healthcare, positive momentum was established or sustained in a number of business segments, with strong revenue growth, prudent management of operating expenses, and strategic investments to drive continued future growth and an improved health care experience for customers and physicians. Mr. Evanko continued to cultivate critical talent, including the assimilation and development of a number of key leaders in both the finance and Cigna Healthcare organizations. As a result of Mr. Evanko’s contributions in 2024, he was awarded a 2024 EIP payment of $1,700,000, or 85% of his target.

Ms. Eder. As Executive Vice President, Global Chief Information Officer, Ms. Eder continued the implementation of the Company’s technology strategy in 2024, which further enabled business value and drove cross-enterprise leverage. Ms. Eder continued to drive patient-centric innovation, including accelerating transformation and capabilities to drive engagement, digital-first, virtual-led experiences, and core and emerging business models. Ms. Eder’s leadership of the combined technology and operations teams resulted in improved real-time, personalized and connected customer, client, and provider experiences, including the launch of new navigation service models, processes to improve accuracy and timeliness, and continued advancement of generative artificial intelligence capabilities. Through Ms. Eder’s leadership, the technology team’s focus on availability, resiliency, security and compliance continued to expand and